Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of JNJ-64530440 in Healthy Japanese Males
NCT03915886Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-64530440 in Chronic Hepatitis B (CHB) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability up to 37 days, Maximum Observed Plasma Analyte Concentration (Cmax) of JNJ-0440 and 11 more. Started Apr 2019; status: terminated.
02
Drugs
JNJ-64530440
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03915886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03915886.